Intermittent Claudication Market

DelveInsight’s Intermittent Claudication market report offers comprehensive coverage of the current treatment practices, emerging drugs, individual Intermittent Claudication therapy market share, and current and forecasted Intermittent Claudication market size from 2018 to 2030, segmented into 7MM (the United States, EU5 (Germany, Spain, Italy, France, and the UK), and Japan).

Some of the Key Highlights from the Intermittent Claudication Market Report

• According to the American College of Cardiology (2020), Peripheral Artery Disease affects 8.5 million people in the United States and becomes more common with age.

• According to the review article “Intermittent Claudication” by Patel et al. (2021), between 10% and 35% of all patients with the peripheral arterial disease will have a presentation of “classic” Intermittent Claudication.

• Various key players such as Venturis Therapeutics, Inc., Pluristem, and others are in the process of developing potential therapies for Intermittent Claudication treatment.

• Pluristem’s PLX-PAD was tested for Intermittent Claudication in a global, randomized, double-blind, placebo-controlled Phase II trial. PLX-PAD is a novel placenta-based cell therapy.

• FGF-1 is being tested by Venturis Therapeutics (Cardiovascular Biotherapeutics) to treat Peripheral Artery Disease with Intermittent Claudication.

Discover more about the disease by requesting for sample @ Intermittent Claudication Pathophysiology

The Intermittent Claudication market report also examines current Intermittent Claudication treatment practices/algorithms, Intermittent Claudication market drivers, Intermittent Claudication market barriers, and unmet medical needs to identify and evaluate the Intermittent Claudication market’s underlying potential.

Intermittent Claudication: Overview

The most common manifestation of Peripheral Artery Disease is Intermittent Claudication, which is defined as activity-induced dysfunction and muscle pain (claudication pain) relieved by rest. The second stage of PAD is Intermittent Claudication, further subdivided into Stage IIa- claudication at a walking distance greater than 200 m and IIb- claudication at a distance of less than 200 m.

Intermittent Claudication Epidemiology Segmentation

The Intermittent Claudication report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Peripheral Artery Disease Total Prevalence 

• Intermittent Claudication Prevalent Population

• Intermittent Claudication Gender-Specific Prevalent Cases

• Intermittent Claudication Diagnosed and Treatable Cases 

Intermittent Claudication Treatment Landscape

The best recommendations for Intermittent Claudication treatment include lifestyle changes such as avoiding saturated fats, not smoking or using tobacco, increasing physical activity, controlling cholesterol, blood sugar, and blood pressure to healthy levels, and maintaining a healthy weight are the best recommendations. Medications to improve blood flow or lower the risk of blood clots are also advised. Some of the FDA-approved drugs that are used for Intermittent Claudication treatment include Pentoxifylline, Pentoxil, Cilostazol, and others.

Intermittent Claudication Market

With an increase in the prevalence of Intermittent Claudication and the high demand for therapies, approval of emerging therapies such as PLX-PAD, FGF-1, and others via novel mechanisms will significantly boost the Intermittent Claudication therapy market size in the forecasted period (2021-2030).

Get the overview about the emerging therapies @ Drugs used to treat Intermittent Claudication 

Intermittent Claudication Pipeline Therapies and Key Companies 

• PLX-PAD: Pluristem

• FGF-1: Venturis Therapeutics, Inc.

Table of Contents 

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Related Reports

Peripheral Artery Disease Market

Get comprehensive historical and forecast analysis of Peripheral Artery Disease Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as lucent Medical Inc., AnGes MG Inc., Bayer AG, Betagenon AB, BiogenCell Ltd, Novartis AG, Reven Pharmaceuticals Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/